Compare Lowe`s Companies Inc (LOW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Organon & Co. Common Stock — how do they compare? Lowe`s Companies Inc trades at $190.49 (market cap $105.89B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lowe`s Companies Inc is far larger — about 29.3× Organon & Co. Common Stock's market cap, and Lowe`s Companies Inc pays the higher dividend (2.65%). Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Organon & Co. Common Stock for 0 Days on average.
| LOW | OGN | |
|---|---|---|
Market Cap | $105.89B | $3.62B |
Volume | 3,104,115 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $13.81 |
52-Week Low | $179.50 | $5.70 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $11.04B |
Dividend Yield | 2.65% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.36, up 1.5% with recent earnings beats but facing industry headwinds. The stock shows bearish technical signals despite positive analyst sentiment with a $244.09 consensus target. Revenue declined to $83.67B in 2025, though net margins remain healthy at 7.35%. Recent drone delivery initiatives with DoorDash and Alphabet aim to enhance competitiveness amid a challenging home improvement market.
LOW presents a value opportunity with reasonable P/E (15.95) and strong cash flow, but risks include declining revenue trends, high debt levels, and housing market sensitivity. Wall Street maintains bullish ratings (61% buy) despite near-term pressure, suggesting potential upside if execution improves.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
